SCHEMBL3236457

SCHEMBL3236457

O=P(O)(O)Cc1nc(Cl)cc(NC2CCOCC2)n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 8/20 0.37
MAPK3 P27361 2/20 0.36
RPS6KA1 Q15418 5/20 0.36
CCNT1 O60563 1/20 0.36
HDAC3 O15379 1/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC2 Q92769 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
CDK2 P24941 6/20 0.34
CCNE1 P24864 5/20 0.34
CNR2 P34972 1/20 0.34
PIM1 P11309 3/20 0.34
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
PIK3CA P42336 1/20 0.33
CDC7 O00311 1/20 0.33
DAPK3 O43293 1/20 0.33
JAK2 O60674 1/20 0.33
ROCK2 O75116 1/20 0.33
PRKD3 O94806 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2019860 0.82 PDE4D (0.39) MAPK1MAPK3RPS6KA1CCNT1CDK2
SCHEMBL3240488 0.82 PIM1 (0.37) MAPK3CCNT1CDK2PIM1CDC7
SCHEMBL3240478 0.82 PIM1 (0.37) MAPK3CCNT1CDK2PIM1CDC7
SCHEMBL3233648 0.80 CHRM3 (0.47) CDK2CCNE1PIK3CA
SCHEMBL2019862 0.76 MAPK1 (0.36) MAPK1MAPK3RPS6KA1CCNT1HDAC3
SCHEMBL3199851 0.73 OPRK1 (0.51) MAPK1CCNT1PIM1MEN1KMT2A
SCHEMBL3231825 0.72 PGK1 (0.42)
SCHEMBL3713155 0.69 TDP1 (0.41) MAPK1MAPK3RPS6KA1CCNT1HDAC3
SCHEMBL2019542 0.67 CCNT1 (0.41) MAPK1MAPK3RPS6KA1CCNT1CDK2
SCHEMBL15229185 0.66 MEN1 (0.71) MAPK1MAPK3CCNT1CDK2CCNE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010027097-A1 TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-03-11 WO disclosed